WNT pathway blockade with porcupine inhibitors is effective in RSPO3-rearranged CRC preclinical models39,40 and clinical trials in patients with RSPO2/3-fusion-positive tumours of any histological origin are ongoing (NCT01351103). The gene discussed is RSPO3; the disease is neoplasm.